Who are we
We are a partnership of experienced senior leaders with long-proven track records in the Ophthalmic space. Value creators with highly impactful networks who provide expertise in strategy, business management, funding, M&A/licensing, regulatory, P&R, commercialization and market access.
CEO & Founder
A native of Boston and long-time resident of Spain, Joe is a strong international business leader and strategist with a proven track record of success in managing multinational and international business organizations.
Prior to founding Emmetropes Joe was Managing Director of Esteve Pharma, which included a wide portfolio across Primary Care, Specialty Care/Ophthalmology & OTC. He was Vice President of Marketing Strategy & Sales at Astra Zeneca in Spain and Director of Alcon Surgical Spain during the years when the company assumed its undisputed leadership position in the market.
Joe was also CEO of European Ophthalmic Services, an innovative healthcare start-up dedicated to providing surgical teams & services to European national healthcare systems as a means to reduce their waiting lists. He was Founder and Managing Partner of Sullivan Advisory Group, a boutique management consulting firm which developed strategies for organizations in private, public & non-profit sectors around the world, including the United Nations World Food Program, headquartered in Rome.
He is a dynamic executive with an inspirational leadership style and a reputation for building and retaining highly motivated Teams.
Joe holds a BS/BA from Framingham State University in Biology and post-graduate Program at George Washington University in Strategic Management.
Mark is an experienced bio-pharmaceutical professional with a 20 year trajectory in business development, business building, R&D management and strategy. Earlier in Mark’s career he was a research scientist for almost a decade, both in academia and biotechnology, before moving into business.
As Head of Corporate Development at Esteve Mark oversaw the development of joint ventures, licensing transactions (both in and out) and supported all M&A opportunities. Milestones in Mark’s career at Esteve include the establishment of Esteve-Teijin Healthcare, a new entity in the Spanish market to deliver Home Respiratory Therapy, the planning of a VC-backed spinout for Esteve’s pipeline of Gene Therapeutics and the signing of a 3-asset outlicensing deal, the largest such deal in Esteve’s history. Most recently he was coordinating the pre-launch activities of Esteve’s proprietary acute pain product (CTC), including all BD activities related to the product. Mark’s experience in Ophthalmology comes from the development of an expansion strategy in the field that included key enabling transactions to secure portfolio.
Prior to Esteve Mark was an Associate Principal with McKinsey and Company in New York. As a member of McKinsey’s Pharmaceutical and Medical Product Practice Mark had a focus on R&D strategy and portfolio management, serving senior management at top tier pharmaceutical, specialty pharmaceutical and biotechnology companies.
Mark has a BA in Biochemistry from the University of Oxford and a DPhil from the Sir William Dunn School of Pathology also at the University of Oxford. Postdoctoral research was carried out at Memorial Sloan Kettering Cancer Center in New York.
COO & Partner
Santi has been leading successful companies, large and small, for nearly 30 years. As General Manager at Winterthur Health and Chief Sales Officer at Winterthur Group, he oversaw business turnover in excess of 1.6B euros. After the acquisition of Winterthur by Axa, Santi became General Manager of Agrupaciò Health, overseeing their extensive geographic and portfolio expansion.
Santi’s focus on ophthalmology began in 1989 in the areas of manufacturing, R&D and sales & marketing. As Surgical Manager for Alcon he was responsible for launching top class products such as AcrySof, DuoVisc and Custom Pak, all of which became gold standards with dominant market positions. Later, under his tenure as Director of Alcon Surgical, the business grew three times over the market rate and consolidated the company in its leadership position.
As Director of Esteve Pharma’s Specialty Care franchise, which included Ophthalmology, Santi oversaw the incorporation and commercial development of top-class products in categories of dry eye, allergy, retinal disorders and glaucoma, once again, ensuring that company growth outpaced that of the market.
Santi has a BS in Pharmacy at Barcelona University and a MBA from ESADE Business School majoring in Marketing. He has carried out extensive international training in marketing, sales and leadership both in Europe and in USA. Santiago speaks Spanish and Catalan and is fluent in English and French.
The commitment and desire to contribute to people's health are behind Jordi's more than 30 years of uninterrupted connection with the health industry, in companies such as Otsuka, Alcon or Novartis.
Curiosity and the need to learn have led Jordi to live intense professional experiences in these companies, in such diverse areas as clinical research, marketing, professional education or strategic analysis. On the other hand, the search for challenges and the passion for innovation have led him to design and patent various solutions in eye health and to market some of them with his own start-up, Oculeed.
Finally, his enthusiastic vocation to share knowledge explains his prolonged dedication to teaching, as a university professor at Tecnocampus-UPF, in business management and neuromarketing areas. However, Jordi's goal, beyond knowledge, is to promote solid and ethical values in the new generations of entrepreneurs and marketing professionals.
Jordi holds a Bachelor's degree in Pharmacy from the University of Barcelona and a Degree in Business Administration and Innovation Management from Tecnocampus-Pompeu Fabra University in Barcelona.
Mike Southard is a business leader with over 35 years of successful experience in the Ophthalmic Surgery and Pharmaceutical Market. 25 years of Mike’s experience were acquired at Alcon, where he rose through the ranks to the position of Vice President, Global Marketing for all Surgical Products (Cataract, Retina, & Surgical Disposables). During Mike’s tenure, the business, both International and U.S. had record, successive, year over year growth and Market Share leadership in almost every market in the World.
Mike is actively involved in M&A and has a well-honed approach to Business Development. He employs a process that delivers an effective and implementable strategy, supported by deep dive tactical approach that can deliver broad success within a defined budget.
Mike currently provides advising services (XMNinc) for several companies working in Ophthalmology and other areas of medicine (Dermatology, Orthopedics and Consumer). He also serves on several Boards as well as Scientific Advisory Boards. Mike is an avid inventor and holds many patents spanning across different areas of healthcare. He has been an author in Ophthalmic Textbooks as well as a speaker at Major Conferences around the world.
Mike holds a BS from Oregon State University and an executive MBA from Stanford (SEP program).
Janet Conway, Ph.D. has acquired a remarkable level of expertise in the area of Ophthalmic Innovation and has provided valuable leadership, guidance and insight to some of the most relevant companies in the space. She has served as Global Head of Ophthalmic Business Development at Pfizer and Pharmacia as well as interim Head of Business Development at Bausch & Lomb. She was a member of the Board of Directors at Aerie Pharmaceuticals and was also Head of Product Development at IOLAB Ophthalmic Pharmaceuticals (J&J), Olympus Medical Instrument Division (US), VimRx Pharmaceuticals, M6 Pharmaceuticals, and a member of the business development team at J&J World Wide Vision Care Franchise. She has advised extensively with The Magnum Group.
Dr. Conway received her Ph.D. in visual neurophysiology from the Massachusetts Institute of Technology and completed a post-doctoral fellowship in visual neuroscience at the University of California Irvine. Following her post-doctoral training she joined Allergan as a Drug Discovery Scientist. She has provided consulting services to numerous pharmaceutical companies in the US and Europe for over 15 years.
Marc Juriy Bunge
Marc is a dynamic senior executive with a deep understanding of the medical technology industry and the hospital sector. He was CEO at Fritz Ruck Ophthalmologische Systeme GmbH (Germany), a leading European Ophthalmic company dedicated to the design, manufacturing and commercialization of Ophthalmic Surgical Equipment. During his tenure at Ruck Marc oversaw the expansion and eventual M&A aspirations of the company until its sale to Hoya Surgical Optics in 2018.
Prior to Ruck, Marc was Managing Partner at Tetris Consulting a Human Resources firm with focus in Health Care and Technology. He was also a Partner at Plambeck, Schumann & Socien and Head of Sales at Technomed GmbH.
Over the years Marc acquired profound experience in product development, distribution, sales, marketing and M&A activities.
Marc is summa cum laude graduated in Political Science, Sociology and Law by the Johann Wolfgang Goethe University in Frankfurt, Germany.
Senior Medical Advisor
Anna is an Ophthalmologist with over 10 years of first-hand experience in the management of ophthalmic diseases, obtained in both hospital and clinical settings.
During her medical career, she combined her clinical practice with research on treatment and molecular mechanisms of inflammatory eye and orbit disorders at Instut Clínic d’Oftalmologia and University of Barcelona.
She has a proven track-record of drafting and supervising clinical development plans, as well as performing scientific and clinical quality assessment of ophthalmic products for the pharmaceutical industry. She gained her expertise working as a Clinical Research Physician at Esteve Pharmaceuticals and as an independent Medical Advisor for Laboratorios Salvat and TFS Contract Research Organization.
Anna greatly enjoys the process of placing a new therapeutic option in the hands of practitioners for their patients, beginning from early development, through the late clinical phases until commercialization and post-marketing activities. She is highly effective in translating unmet medical needs to target product profiles and clinical development drafts.
She holds an M.D. from the Medical School at Universitat Autònoma de Barcelona. She had specialized as an ophthalmologist through the official residency program at Hospital Clínic de Barcelona, from which she received the Emili Letang Award and a research grant that allowed her to lead and develop an investigation project on biologic treatment for thyroid eye disease. She received her PhD in ophthalmology from University of Barcelona.
Anna speaks Polish, English, Spanish and Catalan and enjoys the energy of a dynamic and multicultural working environment.